Li, H., S. Du, L. Yang, Y. Chen, W. Huang, R. Zhang, et al. 2009. Rapid pulmonary fibrosis induced by acute lung injury via a lipopolysaccharide three-hit regimen. Innate Immunity 15: 143–154.
Chi, X.J., J. Cai, C.F. Luo, N. Cheng, Z.Q. Hei, S.R. Li, et al. 2009. Relationship between the expression of Toll-like receptor 2 and 4 in mononuclear cells and postoperative acute lung injury in orthotopic liver transplantation. Chinese Medical Journal 122: 895–899.
Wang, D., J. Lou, C. Ouyang, W. Chen, Y. Liu, X. Liu, et al. 2010. Ras-related protein Rab10 facilitates TLR4 signaling by promoting replenishment of TLR4 onto the plasma membrane. Proceedings of the National Academy of Sciences of the United States of America 107: 13806–13811.
Lorne, E., H. Dupont, and E. Abraham. 2010. Toll-like receptors 2 and 4: Initiators of non-septic inflammation in critical care medicine? Intensive Care Medicine 36: 1826–1835.
Dauphinee, S.M., and A. Karsan. 2006. Lipopolysaccharide signaling in endothelial cells. Laboratory Investigation 86: 9–22.
Blank, R., and L.M. Napolitano. 2011. Epidemiology of ARDS and ALI. Critical Care Clinics 27: 439–458.
Peter, J.V., P. John, P.L. Graham, J.L. Moran, I.A. George, A. Bersten, et al. 2008. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: Meta-analysis. BMJ 336: 1006–1009.
Shashikant, B.N., T.L. Miller, M.J. Jeng, J. Davis, T.H. Shaffer, M.R. Wolfson, et al. 2005. Differential impact of perfluorochemical physical properties on the physiologic, histologic, and inflammatory profile in acute lung injury. Critical Care Medicine 33: 1096–1103.
von der Hardt, K., E. Schoof, M.A. Kandler, J. Dötsch, and W. Rascher. 2002. Aerosolized perfluorocarbon suppresses early pulmonary inflammatory response in a surfactant depleted piglet model. Pediatric Research 51: 177–182.
Qin, X., and Y.N. Liu. 2007. Effect of vaporized perfluorocarbon inspiration on cell apoptosis of intestine mucosa: Experiment with pigs with acute lung injury. Zhonghua Yi Xue Za Zhi 87: 493–496.
Chang, H., F.C. Kuo, Y.S. Lai, and T.C. Chou. 2005. Inhibition of inflammatory responses by FC-77, a perfluorochemical, in lipopolysaccharide-treated RAW 264.7 macrophages. Intensive Care Medicine 31: 977–984.
Gale, S.C., G.D. Gorman, J.G. Copeland, and P.F. McDonagh. 2007. Perflubron emulsion prevents PMN activation and improves myocardial functional recovery after cold ischemia and reperfusion. Journal of Surgical Research 138: 135–140.
Lou, J.N., N. Mili, C. Decrind, Y. Donati, S. Kossodo, A. Spiliopoulos, et al. 1998. An improved method for isolation of microvascular endothelial cells from normal and inflamed human lung. In Vitro Cellular & Developmental Biology. Animal 4: 529–536.
Kim, N.S., and S.J. Kim. 1991. Isolation and cultivation of microvascular endothelial cells from rat lungs: Effects of gelatin substratum and serum. Yonsei Medical Journal 32: 303–314.
Schmittgen, T.D., and K.J. Livak. 2008. Analyzing real-time PCR data by the comparative C(T) method. Nature Protocols 3: 1101–1108.
Poltorak, A., X. He, I. Smirnova, M.Y. Liu, C. Van Huffel, X. Du, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 282: 2085–2088.
Chow, J.C., D.W. Young, D.T. Golenbock, W.J. Christ, and F. Gusovsky. 1999. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. Journal of Biological Chemistry 274: 10689–10692.
Bosma, K.J., and J.F. Lewis. 2007. Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opinion on Emerging Drugs 12: 461–477.
Babu, P.B., A. Chidekel, and T.H. Shaffer. 2005. Hyperoxia-induced changes in human airway epithelial cells: The protective effect of perflubron. Pediatric Critical Care Medicine 6: 188–194.
von der Hardt, K., M.A. Kandler, L. Fink, E. Schoof, J. Dotsch, R.M. Bohle, et al. 2003. Laser-assisted microdissection and real-time PCR detect anti-inflammatory effect of perfluorocarbon. American Journal of Physiology. Lung Cellular and Molecular Physiology 285: L55–L62.
Nakata, S., K. Yasui, T. Nakamura, N. Kubota, and A. Baba. 2007. Perfluorocarbon suppresses lipopolysaccharide- and alpha-toxin-induced interleukin-8 release from alveolar epithelial cells. Neonatology 91: 127–133.
Rotta, A.T., B. Gunnarsson, B.P. Fuhrman, B. Wiryawan, L.J. Hernan, and D.M. Steinhorn. 2003. Perfluorooctyl bromide (perflubron) attenuates oxidative injury to biological and nonbiological systems. Pediatric Critical Care Medicine 4: 233–238.
Wissel, H., W. Burkhardt, J. Rupp, R.R. Wauer, and M. Rüdiger. 2006. Perfluorocarbons decrease Chlamydophila pneumoniae-mediated inflammatory responses of rat type II pneumocytes in vitro. Pediatric Research 60: 264–269.
Haufe, D., T. Luther, M. Kotzsch, L. Knels, and T. Koch. 2004. Perfluorocarbon attenuates response of concanavalin A-stimulated mononuclear blood cells without altering ligand-receptor interaction. American Journal of Physiology. Lung Cellular and Molecular Physiology 287: L210–L216.
Rüdiger, M., H. Wissel, M. Ochs, W. Burkhardt, H. Proquitté, R.R. Wauer, et al. 2003. Perfluorocarbons are taken up by isolated type II pneumocytes and influence its liquid synthesis and secretion. Critical Care Medicine 31: 1190–1196.